Prokidney Corp. company information, Employees & Contact Information

ProKidney Corp. to Present Late-Breaking Phase 2 REGEN-007 Study Results at ASN Kidney Week 2025 Quiver Quantitative

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 Sahm

Late‑Breaking Phase 2 REGEN‑007 Results: ProKidney to Present Two Posters at ASN Kidney Week Nov 6 Stock Titan

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference Yahoo Finance

ProKidney’s Diabetes and CKD Cell Therapy Rilparencel Improves eGFR Slope Annual Decline in Phase 2 Trial CGTLive®

Rilparencel De-Risks Phase 3 As ProKidney Enters Price Discovery (Technical Analysis) Seeking Alpha

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware Yahoo Finance

Leading CKD Cell Therapy Company ProKidney Set for Major Healthcare Conference Appearances in September Stock Titan

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights Yahoo Finance

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference Stock Titan

ProKidney's Breakthrough: FDA Backs Fast-Track Path as Kidney Treatment Shows Strong Phase 2 Results Stock Titan

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes GlobeNewswire

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates GlobeNewswire

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference GlobeNewswire

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel GlobeNewswire

ProKidney Corp. Completes Domestication from Cayman Islands to Delaware, Retaining Nasdaq Trading Symbol "PROK" Nasdaq

ProKidney Corp. Management to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference Nasdaq

Clinical Trial Breakthrough: ProKidney's Rilparencel Halts Kidney Disease Progression with 78% Improvement Stock Titan

ProKidney Strengthens U.S. Presence: Strategic Shift from Cayman Islands to Delaware Complete Stock Titan

ProKidney Reports Full Year 2024 Financial Results and Business Highlights GlobeNewswire

FDA Fast-Tracks Revolutionary Kidney Disease Treatment: ProKidney's Diabetes Therapy Advances Toward Approval Stock Titan

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation Yahoo Finance

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights Stock Titan

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire

ProKidney Corp. CEO to Present at 43rd Annual J.P. Morgan Healthcare Conference Quiver Quantitative

Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 Trial HCPLive

ProKidney Puts Focus on US Trial for T2D and CKD Cell Therapy Rilparencel CGTLive®

ProKidney Appoints Nikhil Pereira-Kamath, MBA, As Chief Business Officer citybiz

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates Stock Titan

ProKidney Appoints Dr. John M. Maraganore And Jennifer Fox To Its Board Of Directors citybiz

PROK - ProKidney Latest Stock News & Market Updates Stock Titan

ProKidney (PROK) Stock Price, News & Analysis MarketBeat

PROK Stock Price and Chart — NASDAQ:PROK TradingView